Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer

Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer

The efficacy and safety of olaratumab plus nabpaclitaxel and gemcitabine in treatment-naïve participants with metastatic pancreatic ductal adenocarcinoma was evaluated. An initial phase 1b dose-escalation trial was conducted to determine the olaratumab dose for the phase 2 trial, a randomized, doubl...

Full description

Bibliographic Details
Main Authors: Faithlore P. Gardner, Zev A. Wainberg, Christos Fountzilas, Nathan Bahary, Mark S. Womack, Teresa Macarulla, Ignacio Garrido-Laguna, Patrick M. Peterson, Erkut Borazanci, Melissa Johnson, Matteo Ceccarelli, Uwe Pelzer
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Cancers
Subjects:
olaratumab
gemcitabine
nabpaclitaxel
metastatic pancreatic cancer
Online Access:https://www.mdpi.com/2072-6694/16/7/1323

Internet

https://www.mdpi.com/2072-6694/16/7/1323

Similar Items